Literature DB >> 11000462

Experimental study on the possibility of treatment of some hemorrhagic fevers.

G Ignatyev1, A Steinkasserer, M Streltsova, A Atrasheuskaya, A Agafonov, W Lubitz.   

Abstract

After intracerebral challenge with 100 PFU of Lassa virus (strain Josiah), all infected mice (CBA/calac) died (control group). Production of pro-inflammatory cytokines (IL-1beta, TNF-alpha) significantly increased in the blood of these mice during the infection. For neutralization of increasing concentrations of these cytokines recombinant IL-1RA was used intraperitonealy at a dose 100 microg kg(-1), everyday, within 5 days from the third day after the challenge. Injections of IL-1RA decreased the concentration of IL-1beta and TNF-alpha and resulted in survival of all infected mice (treatment group). Marburg fever (strain Popp) caused in guinea pigs by 5 LD(50) of virus lead to the significant increase of TNF-alpha in the animal's blood and caused a lethal outcome (control group). Treatment of infected guinea pigs by IL-1RA or anti-TNF serum decreased the concentration of TNF-alpha and resulted in survival of half of the animals (treatment group). For the treatment recombinant IL-1RA was used at a dose 100 microg kg(-1), intramuscularly, everyday, within 6 days from the third day after the challenge or anti-TNF serum, intramuscularly 0.5 ml (2000 U ml(-1); 1 U of the antiserum neutralises 0.03 ng of TNF-alpha), everyday, within 6 days from the third day after the challenge.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11000462     DOI: 10.1016/s0168-1656(00)00300-x

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  10 in total

1.  Clinical aspects of Marburg hemorrhagic fever.

Authors:  Masfique Mehedi; Allison Groseth; Heinz Feldmann; Hideki Ebihara
Journal:  Future Virol       Date:  2011-09       Impact factor: 1.831

Review 2.  Ebola haemorrhagic fever.

Authors:  Heinz Feldmann; Thomas W Geisbert
Journal:  Lancet       Date:  2011-03-05       Impact factor: 79.321

Review 3.  Pathogenesis of malaria and clinically similar conditions.

Authors:  Ian A Clark; Lisa M Alleva; Alison C Mills; William B Cowden
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

4.  Changes in immune parameters and their correction in human cases of tick-borne encephalitis.

Authors:  A V Atrasheuskaya; T M Fredeking; G M Ignatyev
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

5.  Capacity building permitting comprehensive monitoring of a severe case of Lassa hemorrhagic fever in Sierra Leone with a positive outcome: case report.

Authors:  Jessica N Grove; Luis M Branco; Matt L Boisen; Ivana J Muncy; Lee A Henderson; John S Schieffellin; James E Robinson; James J Bangura; Mbalu Fonnie; Randal J Schoepp; Lisa E Hensley; Alhassan Seisay; Joseph N Fair; Robert F Garry
Journal:  Virol J       Date:  2011-06-20       Impact factor: 4.099

6.  Genome-wide scans provide evidence for positive selection of genes implicated in Lassa fever.

Authors:  Kristian G Andersen; Ilya Shylakhter; Shervin Tabrizi; Sharon R Grossman; Christian T Happi; Pardis C Sabeti
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2012-03-19       Impact factor: 6.237

Review 7.  The Role of Cytokines and Chemokines in Filovirus Infection.

Authors:  Sandra L Bixler; Arthur J Goff
Journal:  Viruses       Date:  2015-10-23       Impact factor: 5.048

8.  Diagnostic proficiency and reporting of Lassa fever by physicians in Osun State of Nigeria.

Authors:  Samuel Anu Olowookere; Akinola Ayoola Fatiregun; Olalere Omoyosola Gbolahan; Ebenezer Gbenga Adepoju
Journal:  BMC Infect Dis       Date:  2014-06-20       Impact factor: 3.090

Review 9.  Ebola virus disease: an update for anesthesiologists and intensivists.

Authors:  Duane J Funk; Anand Kumar
Journal:  Can J Anaesth       Date:  2014-11-06       Impact factor: 5.063

Review 10.  Updates in diagnosis and management of Ebola hemorrhagic fever.

Authors:  Salah Mohamed El Sayed; Ali A Abdelrahman; Hani Adnan Ozbak; Hassan Abdullah Hemeg; Ali Mohammed Kheyami; Nasser Rezk; Mohamed Baioumy El-Ghoul; Manal Mohamed Helmy Nabo; Yasser Mohamed Fathy
Journal:  J Res Med Sci       Date:  2016-10-18       Impact factor: 1.852

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.